Judit Moldvay

Summary

Publications

  1. ncbi request reprint Immunophenotypic profiling of nonsmall cell lung cancer progression using the tissue microarray approach
    Judit Papay
    Department of Pathology, Semmelweis University, Budapest, Hungary
    Appl Immunohistochem Mol Morphol 15:19-30. 2007
  2. doi request reprint [Analysis of drug therapy of lung cancer in Hungary]
    Judit Moldvay
    Pulmonológiai Klinika, Semmelweis Egyetem, Budapest, Hungary
    Magy Onkol 57:33-8. 2013
  3. doi request reprint [Personalized therapy in non-small cell lung cancer: from diagnosis to therapy]
    Judit Moldvay
    Semmelweis Egyetem, Általános Orvostudományi Kar Pulmonológiai Klinika, Budapest
    Orv Hetil 153:909-16. 2012
  4. doi request reprint [EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance]
    Judit Moldvay
    Semmelweis Egyetem Pulmonológiai Klinika, Budapest, Hungary
    Magy Onkol 56:38-49. 2012
  5. doi request reprint [Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy]
    Judit Moldvay
    Pulmonológiai Klinika, Semmelweis Egyetem, Budapest, Hungary
    Magy Onkol 55:105-9. 2011
  6. ncbi request reprint [Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy]
    Judit Moldvay
    Pulmonológiai Klinika, Semmelweis Egyetem, Budapest, Hungary
    Magy Onkol 51:191-6. 2007
  7. ncbi request reprint Distinct claudin expression profile in histologic subtypes of lung cancer
    Judit Moldvay
    Department of Pulmonology, Semmelweis University Budapest, Budapest, Diósárok u 1 c H 1125, Hungary
    Lung Cancer 57:159-67. 2007
  8. ncbi request reprint The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas
    Judit Moldvay
    County Hospital of Pulmonology, Törökbálint, Hungary
    Pathol Oncol Res 10:85-8. 2004
  9. doi request reprint Platinum-based chemotherapy in lung cancer affects the expression of certain biomarkers including ERCC1
    Judit Papay
    I Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
    Pathol Oncol Res 15:445-50. 2009
  10. pmc Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry
    Ferenc Pinter
    KPS Medical Biotechnology and Healthcare Services, Budapest, Hungary
    J Mol Diagn 10:160-8. 2008

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Immunophenotypic profiling of nonsmall cell lung cancer progression using the tissue microarray approach
    Judit Papay
    Department of Pathology, Semmelweis University, Budapest, Hungary
    Appl Immunohistochem Mol Morphol 15:19-30. 2007
    ..Unsupervised immunoprofiles based on differentially expressed biomarkers may help selecting lung cancers with aggressive behavior...
  2. doi request reprint [Analysis of drug therapy of lung cancer in Hungary]
    Judit Moldvay
    Pulmonológiai Klinika, Semmelweis Egyetem, Budapest, Hungary
    Magy Onkol 57:33-8. 2013
    ..Further detailed analysis of the available data may help to obtain more accurate picture of the efficacy of lung cancer treatments as well...
  3. doi request reprint [Personalized therapy in non-small cell lung cancer: from diagnosis to therapy]
    Judit Moldvay
    Semmelweis Egyetem, Általános Orvostudományi Kar Pulmonológiai Klinika, Budapest
    Orv Hetil 153:909-16. 2012
    ..In these days, we are experiencing a turbulent era of onco-pulmonology, which - despite all difficulties - gives hope for both patients and clinicians...
  4. doi request reprint [EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance]
    Judit Moldvay
    Semmelweis Egyetem Pulmonológiai Klinika, Budapest, Hungary
    Magy Onkol 56:38-49. 2012
    ....
  5. doi request reprint [Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy]
    Judit Moldvay
    Pulmonológiai Klinika, Semmelweis Egyetem, Budapest, Hungary
    Magy Onkol 55:105-9. 2011
    ..This knowledge might be of importance when designing treatment protocols for non-small cell lung cancer patients...
  6. ncbi request reprint [Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy]
    Judit Moldvay
    Pulmonológiai Klinika, Semmelweis Egyetem, Budapest, Hungary
    Magy Onkol 51:191-6. 2007
    ..Our results may help to determine the most cost-effective way of patient selection in case of non-small cell lung cancer patients requiring second line therapy; moreover, they might serve as a basis for further economic analyses...
  7. ncbi request reprint Distinct claudin expression profile in histologic subtypes of lung cancer
    Judit Moldvay
    Department of Pulmonology, Semmelweis University Budapest, Budapest, Diósárok u 1 c H 1125, Hungary
    Lung Cancer 57:159-67. 2007
    ..Claudins are the main constituents of tight junctions. Little is known about their expression and localization in the normal bronchial epithelium and in lung cancer...
  8. ncbi request reprint The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas
    Judit Moldvay
    County Hospital of Pulmonology, Törökbálint, Hungary
    Pathol Oncol Res 10:85-8. 2004
    ..Our results confirm that TTF-1 immunohistochemistry is a very sensitive and highly specific method in the differential diagnosis of primary and metastatic lung adenocarcinomas and should be used in the everyday clinical practice...
  9. doi request reprint Platinum-based chemotherapy in lung cancer affects the expression of certain biomarkers including ERCC1
    Judit Papay
    I Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
    Pathol Oncol Res 15:445-50. 2009
    ....
  10. pmc Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry
    Ferenc Pinter
    KPS Medical Biotechnology and Healthcare Services, Budapest, Hungary
    J Mol Diagn 10:160-8. 2008
    ..These results indicate that molecular diagnostic methods appear to be most important for the identification of lung adenocarcinoma patients who may benefit from EGFR inhibitor treatments...
  11. ncbi request reprint Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx in paraffin-embedded cancer tissues
    Katalin Derecskei
    Department of Tumor Progression, National Institute of Oncology, Budapest, H 1122, Hungary
    Pathol Oncol Res 12:243-6. 2006
    ..Accordingly, we recommend retesting cases negative for EGFR with EGFR pharmDxTM using protocol modifications optimizing antigen retrieval and the incubation periods...
  12. ncbi request reprint [Epidermal growth factor receptor (EGFR): therapeutic target in the treatment of lung adenocarcinoma]
    Richard Schwab
    Semmelweis Egyetem, Általános Orvostudományi Kar, I Patológiai és Kísérleti Rákkutató Intézet
    Orv Hetil 146:2335-42. 2005
    ..The basis of the effective therapy is the identification of the mutations. The clinical advantage of EGFR is an example from the coming age of tumor chemotherapy, when the presence of molecular targets will guide the therapeutic choice...
  13. ncbi request reprint [Our experience using autofluorescence bronchoscopy]
    Gabor Kovacs
    Pest Megyei Tüdőgyógyintézet, Törökbálint
    Orv Hetil 145:1473-8. 2004
    ..Lung cancer is responsible for most cancer deaths in the world. The main reason for the poor prognosis is late diagnosis. Many patients could be successfully treated in early stage...